Wilmington-based Incyte looking to repurpose flagship drug as COVID-19 treatment By: Philadelphia Business Journal via Business Journals April 03, 2020 at 10:55 AM EDT The Wilmington biopharmaceutical company's stock opened up about 2% at $77.59 per share Friday morning. Read More >>
